Ethan Basch joins UNC Lineberger to lead cancer outcomes research program
Basch comes to UNC from the Memorial Sloan-Kettering Cancer Center where he was an attending physician at Memorial Hospital and an associate professor of public health at Weill Cornell Medical College.
Dr. Basch is a medical oncologist and health services researcher. His clinical expertise is prostate cancer, and his research expertise includes patient-reported outcomes, drug regulatory policy, and comparative effectiveness research.
Basch said, “I am excited to join an accomplished and dynamic group of cancer outcomes researchers at UNC, and to help further develop a world class research program here.”
“In addition to being an outstanding addition to our urologic oncology program, Dr. Basch’s focus on improving how we measure patient outcomes in clinical trials and in the practice of cancer care reflects UNC’s commitment to continuously assessing how we treat patients and moving the field forward,” said Lisa A. Carey, MD, associate director of clinical research at UNC Lineberger and physician-in-chief of the N.C. Cancer Hospital.
Shelley Earp, MD, director of UNC Lineberger, said, “We are thrilled to have Dr. Basch bring his national leadership in outcomes research to UNC, joining a team that spans multiple schools, colleges, and disciplines with the goal of discovering what really works in cancer care through comparative effectiveness research. His expertise in the effort to inform health care decisions, and particularly in integrating the patient perspective, brings additional depth to an already strong team.”
Basch is a federally appointed member of the Methodology Committee of the Patient-Centered Outcomes Research Institute (PCORI), a member of the Board of Directors of the International Society for Quality of Life Research (ISOQOL), Co-Chair of the Health Outcomes Committee of the Alliance for Clinical Trials in Oncology, and a member of the Board of Scientific Advisors of the National Cancer Institute. He leads an ongoing NCI initiative to develop a patient-reported adverse event monitoring system for use in clinical research (the “PRO-CTCAE”), and is study chair for multiple trials employing patient-reported endpoints.
He earned an undergraduate degree at Brown University and a M.Phil. at Oxford University. He is a graduate of Harvard Medical School and the Harvard School of Public Health. He completed his residency at Massachusetts General Hospital, and fellowship in Oncology at Memorial Sloan-Kettering Cancer Center.